[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
January 20, 2015

Hematopoietic Stem Cell Transplantation for MS: Extraordinary Evidence Still Needed

Author Affiliations
  • 1Department of Neurology, University of California, San Francisco

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2015;313(3):251-252. doi:10.1001/jama.2014.18150

Multiple sclerosis (MS) is a central nervous system disorder characterized by inflammation, loss of the insulating tissue (myelin) surrounding and protecting nerve axons, and multifocal scarring.1 Multiple sclerosis is a prototypic autoimmune disease likely mediated by pathogenic T and B lymphocytes. There has been substantial progress in the management of MS during the past decade, with 10 variably effective therapies now available and approved by the US Food and Drug Administration (FDA). These therapies suppress the early relapsing-remitting form of MS; however, the late neurodegenerative phase of the disease, progressive MS, remains largely untreatable.